Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials

Arthritis and Rheumatology

Volumn 69, Issue 10, 2017, Pages 1949-1959

  Vanhoutte, Frédéric ^a   Mazur, Minodora ^b   Voloshyn, Oleksandr ^c   Stanislavchuk, Mykola ^d   Van der Aa, Annegret ^a   Namour, Florence ^e   Galien, René ^e   Meuleners, Luc ^a   van 't Klooster, Gerben ^a  

^a GALAPAGOS NV   (Belgium)

^b University Hospital   (Moldova)

^c Chernivtsi Regional Clinical Hospital   (Ukraine)

^d Vinnytsia Regional Clinical Hospital   (Ukraine)

^e Galapagos SASU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; FILGOTINIB; GS 6034; HIGH DENSITY LIPOPROTEIN; JANUS KINASE 1; METHOTREXATE; PLACEBO; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; ANTIRHEUMATIC AGENT; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; AMYLASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CONTROLLED STUDY; CYSTITIS; DAS28; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENOGASTRIC REFLUX; DYSGEUSIA; ENZYME INHIBITION; FEMALE; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL PAIN; GINGIVA BLEEDING; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; INFECTION; INFESTATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPPER ABDOMINAL PAIN; UROGENITAL TRACT DISEASE; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMBINATION DRUG THERAPY; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JANUS KINASE 1; MALE; METHOTREXATE; MIDDLE AGED; PYRIDINES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 85030986039     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40186     Document Type: Article

References (38)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356–61.
2. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473–88.
3. Koenders MI, van den Berg WB. Novel therapeutic targets in rheumatoid arthritis. Trends Pharmacol Sci 2015;36:189–95.
4. Kyttaris VC. Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther 2012;6:245–50.
5. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Ann Rev Med 2015;66:311–28.
6. Kaur K, Kalra S, Kaushal S. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis. Clin Ther 2014;36:1074–86.
7. Vyas D, O'Dell KM, Bandy JL, Boyce EG. Tofacitinib: the first janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2013;47:1524–31.
8. Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs 2014;23:1067–77.
9. Grisouard J, Hao-Shen H, Dirnhofer S, Wagner KU, Skoda RC. Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica 2014;99:e52–4.
10. Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K. JAK2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998;93:397–409.
11. Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013;191:3568–77.
12. Namour F, Diderichsen PM, Cox E, Vayssière B, van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet 2015;54:859–74.
13. Namour F, Galien R, Gheyle L, Vanhoutte F, Vayssiere B, van der Aa A, et al. Once daily high dose regimens of GLPG0634 in healthy volunteers are safe and provide continuous inhibition of JAK1 but not JAK2 [abstract]. Arthritis Rheum 2012;64 Suppl:S573.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
15. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
16. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
17. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729–40.
18. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.
19. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012;64:970–81.
20. Keystone E, Taylor P, Genovese M, Schlichting D, Beattie S, Gaich C, et al. 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional DMARDS in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2012;71 Suppl 3:152.
21. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo [published erratum appears in Arthritis Rheum 2012;64:1487]. Arthritis Rheum 2009;60:1895–905.
22. Popa CD, Arts E, Fransen J, van Riel PL. Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals. Mediators Inflamm 2012;2012:785946.
23. McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. In Press.
24. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998;93:373–83.
25. Schnoor M, Alcaide P, Voisin MB, van Buul JD. Crossing the vascular wall: common and unique mechanisms exploited by different leukocyte subsets during extravasation. Mediators Inflamm 2015;2015:946509.
26. Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol 2016;68:2857–66.
27. Navarro-Hernández RE, Oregon-Romero E, Vázquez-Del Mercado M, Rangel-Villalobos H, Palafox-Sánchez CA, Muñoz-Valle JF. Expression of ICAM1 and VCAM1 serum levels in rheumatoid arthritis clinical activity: association with genetic polymorphisms. Dis Markers 2009;26:119–26.
28. Ally MM, Hodkinson B, Meyer PW, Musenge E, Tikly M, Anderson R. Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis. Mediators Inflamm 2013;2013:183653.
29. Väänänen T, Koskinen A, Paukkeri EL, Hämäläinen M, Moilanen T, Moilanen E, et al. YKL-40 as a novel factor associated with inflammation and catabolic mechanisms in osteoarthritic joints. Mediators Inflamm 2014;2014:215140.
30. Kim H, Hawley TS, Hawley RG, Baumann H. Protein tyrosine phosphatase 2 (SHP-2) moderates signaling by gp130 but is not required for the induction of acute-phase plasma protein genes in hepatic cells. Mol Cell Biol 1998;18:1525–33.
31. Singh SK, Bhardwaj R, Wilczynska KM, Dumur CI, Kordula T. A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40. J Biol Chem 2011;286:39893–903.
32. Sivalingam SP, Thumboo J, Vasoo S, Thio ST, Tse C, Fong KY. In vivo pro- and anti-inflammatory cytokines in normal and patients with rheumatoid arthritis. Ann Acad Med Singapore 2007;36:96–9.
33. Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, et al. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther 2010;12:R211.
34. Wagner C, Chen D, Fan H, Hsia EC, Mack M, Emery P, et al. Evaluation of serum biomarkers associated with radiographic progression in methotrexate-naive rheumatoid arthritis patients treated with methotrexate or golimumab. J Rheumatol 2013;40:590–8.
35. Yanagida M, Kawasaki M, Fujishiro M, Miura M, Ikeda K, Nozawa K, et al. Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with tocilizumab: an anti-interleukin-6 receptor antibody. Biomed Res Int 2013;2013:607137.
36. Kirkham BW, Wasko MC, Hsia EC, Fleischmann RM, Genovese MC, Matteson EL, et al. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis 2014;73:161–9.
37. Yamaoka K, Kubo S, Li W, Sonomoto K, Hirata S, Sasso EH, et al. Effects of tofacitinib treatment on leptin and other components of the multi-biomarker disease activity score in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2014;73 Suppl 2:FRI0333.
38. Tanaka Y, Hanami K, Tasaka H, Fukuyo S, Haney DJ, Bolce R, et al. A multi-biomarker disease activity (VECTRA DA algorithm) score reflects clinical disease activity and structural changes in rheumatoid arthritis patients treated with tocilizumab [abstract]. Arthritis Rheum 2012;64 Suppl:S897.